Diary - News All news Imaxio receives scientific advice from the European Medicines Agency

Imaxio receives scientific advice from the European Medicines Agency

Imaxio receives scientific advice from the European Medicines Agency (EMA) for its influenza vaccine candidate IMX836

Imaxio plans to make IMX836 reach the clinic by early 2018

Imaxio, a biotech company specializing in immunology, announces today that it has received scientific advice from the European Medicines Agency (EMA) for IMX836, its vaccine candidate dedicated to the prevention of influenza in humans.

This first scientific advice reinforces Imaxio’s plan to start, by early 2018, a phase I clinical trial involving IMX836.

Read the press release

Headlines

Our members

Lys Therapeutics and Inserm Transfert sign a three-year agreement

March 4^th, 2022

Nosopharm signs partnership with INRAE and University of Montpellier to develop new anti-infectives

March 15^th, 2022

Cellenion Announces Opening of BICO’s First Single Cell Analysis Centre of Excellence

March 9^th, 2022

All news

Imaxio receives scientific advice from the European Medicines Agency